PNH 및 aHUS 시장 보고서 : 동향, 예측, 경쟁 분석(-2031년)

The future of the global PNH and aHUS market looks promising with opportunities in the hospital, specialty clinic, and research institute markets. The global PNH and aHUS market is expected to grow with a CAGR of 11.2% from 2025 to 2031. The major drivers for this market are the increasing prevalence of rare blood disorders, the rising demand for targeted therapies, and the growing awareness of PNH and aHUS.

• Lucintel forecasts that, within the treatment type category, eculizumab is expected to witness higher growth over the forecast period.
• Within the end use category, hospital is expected to witness the highest growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the PNH and aHUS Market

The PNH and aHUS markets are experiencing rapid evolution driven by advancements in diagnostics, targeted therapies, and personalized medicine. Increasing awareness, technological innovations, and regulatory support are fueling growth and expanding treatment options. These developments are not only improving patient outcomes but also reshaping market dynamics, creating new opportunities for stakeholders. As the landscape shifts, understanding emerging trends is crucial for companies, clinicians, and investors aiming to stay ahead in this specialized field. The following key trends highlight the major forces driving change in the PNH and aHUS markets.

• Growing Adoption of Eculizumab and Complement Inhibitors: Eculizumab remains the cornerstone treatment for PNH and aHUS, with increasing adoption due to its proven efficacy. New complement inhibitors are entering the market, offering alternatives with improved safety profiles and dosing convenience. This trend enhances patient access to effective therapies and encourages competition, leading to better pricing and innovation. The expanding use of these drugs is also prompting healthcare providers to update treatment protocols, ultimately improving patient outcomes and quality of life.
• Advances in Diagnostic Technologies: The development of more precise and rapid diagnostic tools, such as genetic testing and biomarker analysis, is transforming disease detection. Early and accurate diagnosis enables timely intervention, reducing disease progression and complications. These technological advancements are also facilitating personalized treatment plans, optimizing therapeutic efficacy. As diagnostics become more accessible and affordable, they are expected to drive earlier diagnosis and better disease management, significantly impacting market growth and patient care standards.
• Rising Focus on Personalized Medicine: Personalized treatment approaches are gaining traction, driven by a deeper understanding of genetic and molecular profiles associated with PNH and aHUS. Tailoring therapies to individual patient characteristics improves efficacy and minimizes adverse effects. This trend encourages the development of targeted therapies and companion diagnostics, fostering innovation. Personalized medicine is also attracting investments and research funding, which accelerates the discovery of novel treatment options, ultimately leading to more effective and patient-centric care.
• Increasing Market Penetration in Emerging Regions: Expanding healthcare infrastructure and rising awareness are driving market growth in emerging regions such as Asia-Pacific and Latin America. Companies are establishing local manufacturing and distribution channels to improve access. Regulatory agencies are also streamlining approval processes, facilitating faster market entry. This regional expansion not only broadens patient access to advanced therapies but also diversifies market revenue streams, making the industry more resilient and competitive on a global scale.
• Regulatory and Reimbursement Developments: Evolving regulatory frameworks and reimbursement policies are shaping market dynamics. Governments and payers are increasingly supporting innovative therapies through favorable reimbursement schemes, encouraging their adoption. Regulatory agencies are also streamlining approval processes for new drugs and diagnostics, reducing time-to-market. These developments are crucial for market sustainability, ensuring that patients receive access to cutting-edge treatments while incentivizing ongoing research and development efforts.

In summary, these emerging trends are collectively transforming the PNH and aHUS markets by enhancing diagnostic accuracy, expanding treatment options, and improving patient access worldwide. They are fostering innovation, increasing competition, and driving growth, ultimately leading to more personalized and effective patient care. As these trends continue to evolve, stakeholders must adapt to capitalize on new opportunities and address ongoing challenges in this dynamic landscape.

Recent Developments in the PNH and aHUS Market

The PNH and aHUS markets have experienced significant evolution driven by advancements in diagnostics, therapeutics, and regulatory approvals. These rare hematological disorders, characterized by complement system dysregulation, demand innovative treatment approaches. Recent developments reflect increased understanding of disease mechanisms, leading to targeted therapies and improved patient outcomes. Market dynamics are also influenced by regulatory support, increased awareness, and expanding clinical applications. As research progresses, the landscape continues to shift, offering new hope for affected patients and creating opportunities for pharmaceutical companies. These key developments are shaping the future trajectory of the PNH and aHUS markets, fostering growth and innovation.

• Introduction of Complement Inhibitors: The approval of novel complement inhibitors like ravulizumab and crovalimab has revolutionized treatment options, offering more effective and longer-lasting therapies. These drugs have improved patient survival rates and reduced disease burden, significantly impacting market growth by expanding the patient base and increasing treatment adherence.
• Advances in Diagnostic Technologies: Enhanced diagnostic tools, including genetic testing and biomarker identification, have enabled earlier and more accurate diagnosis of PNH and aHUS. This has led to timely intervention, personalized treatment plans, and better disease management, ultimately expanding market reach and improving patient outcomes.
• Regulatory Approvals and Reimbursement Policies: Increased regulatory approvals across various regions and supportive reimbursement policies have facilitated wider access to therapies. These developments have reduced treatment costs and barriers, encouraging healthcare providers to adopt new therapies and boosting market penetration.
• Growing Awareness and Patient Advocacy: Rising awareness campaigns and active patient advocacy groups have increased disease recognition, leading to earlier diagnosis and treatment initiation. This has expanded the patient population and driven demand for innovative therapies, positively influencing market growth.
• Research and Development Initiatives: Ongoing R&D efforts focusing on next-generation complement inhibitors and gene therapies are promising new treatment modalities. These innovations aim to improve efficacy, reduce side effects, and potentially cure the diseases, fostering a competitive and dynamic market environment.

In summary, these recent developments are significantly impacting the PNH and aHUS markets by enhancing diagnostic accuracy, expanding treatment options, and improving patient access. The market is poised for continued growth driven by innovation, regulatory support, and increased awareness, ultimately benefiting patients and stakeholders alike.

Strategic Growth Opportunities in the PNH and aHUS Market

The PNH and aHUS market is experiencing rapid evolution driven by advancements in diagnostics, targeted therapies, and personalized medicine. As awareness increases and new treatments emerge, key growth opportunities are shaping the future landscape of this niche yet critical sector. These developments are poised to improve patient outcomes, expand market reach, and foster innovation. Stakeholders are focusing on leveraging these opportunities to address unmet needs and optimize treatment strategies, ultimately transforming the management of PNH and aHUS. The following five key growth opportunities across applications highlight the potential for significant market expansion and improved healthcare delivery.

• Enhanced Diagnostic Technologies: Improving accuracy and early detection of PNH and aHUS enables timely intervention, reducing disease progression and complications. Advanced diagnostic tools, including flow cytometry and genetic testing, are becoming more accessible, leading to better patient stratification and personalized treatment plans. This growth opportunity enhances clinical outcomes and reduces healthcare costs by enabling earlier, targeted therapies.
• Development of Targeted Therapies: The introduction of novel drugs such as complement inhibitors has revolutionized treatment options. Ongoing research into more specific and potent agents promises to improve efficacy and reduce side effects. This opportunity impacts the market by expanding therapeutic options, increasing patient adherence, and driving revenue growth for pharmaceutical companies.
• Personalized Medicine Approaches: Tailoring treatments based on genetic and biomarker profiles allows for more effective management of PNH and aHUS. This approach minimizes adverse effects and maximizes therapeutic benefits. The growth in personalized medicine fosters innovation, attracts investment, and enhances patient satisfaction, ultimately transforming clinical practice.
• Expansion of Market Access and Reimbursement: Increasing awareness and advocacy efforts are improving reimbursement policies and market access for advanced therapies. This growth opportunity ensures broader patient reach and affordability, encouraging adoption of new treatments. It also stimulates market competition and innovation, benefiting patients and providers alike.
• Strategic Collaborations and Partnerships: Collaborations between biotech firms, pharmaceutical companies, and research institutions accelerate drug development and clinical trials. These partnerships facilitate knowledge sharing, resource pooling, and faster commercialization. This growth opportunity enhances innovation pipelines and market competitiveness, leading to more effective treatment options.

In summary, these growth opportunities are significantly impacting the PNH and aHUS market by fostering innovation, improving patient outcomes, and expanding access to advanced therapies. They are driving market growth, attracting investments, and transforming disease management strategies, ultimately benefiting patients and healthcare providers worldwide.

PNH and aHUS Market Driver and Challenges

The PNH and aHUS market is influenced by a complex interplay of technological advancements, economic factors, and regulatory developments. Innovations in targeted therapies have revolutionized treatment options, while economic considerations such as healthcare spending and drug affordability impact market growth. Regulatory policies and approval processes also shape the landscape, affecting the speed and availability of new treatments. Additionally, increasing awareness and diagnosis rates contribute to market expansion. However, challenges such as high treatment costs, stringent regulatory hurdles, and limited patient populations pose significant obstacles. Understanding these drivers and challenges is essential for stakeholders aiming to navigate and capitalize on this evolving market landscape.

The factors responsible for driving the PNH and aHUS market include:

• Technological Innovations: The development of targeted therapies like complement inhibitors has significantly improved patient outcomes. These advancements enable more precise treatment, reducing side effects and increasing efficacy. As research progresses, new drugs and delivery methods are emerging, expanding treatment options. This technological evolution attracts investments and encourages pharmaceutical companies to innovate further, fueling market growth. Moreover, diagnostic tools have improved, allowing earlier and more accurate detection, which increases the patient pool eligible for treatment. Overall, technological progress is a key driver that enhances treatment effectiveness and market potential.
• Increasing Prevalence and Diagnosis: Rising awareness among healthcare professionals and patients has led to increased diagnosis rates of PNH and aHUS. Improved diagnostic techniques, such as flow cytometry and genetic testing, facilitate early detection, enabling timely intervention. As prevalence data becomes more accurate, healthcare providers and policymakers recognize the need for effective treatments, boosting demand. The growing patient population directly correlates with increased market sales and research funding. This trend is further supported by demographic shifts, such as aging populations, which are more susceptible to these rare blood disorders, thereby expanding the market.
• Regulatory Approvals and Support: Favorable regulatory environments and accelerated approval pathways have expedited the availability of new therapies. Regulatory agencies like the FDA and EMA are increasingly supporting orphan drug designations, providing incentives for pharmaceutical companies. This support encourages innovation and reduces time-to-market for novel treatments. Additionally, government initiatives and funding programs aimed at rare diseases promote research and development activities. These regulatory and policy frameworks create a conducive environment for market expansion by ensuring that effective treatments reach patients faster, ultimately driving growth in the PNH and aHUS market.
• Strategic Collaborations and Partnerships: Collaborations between pharmaceutical companies, biotech firms, and research institutions foster innovation and resource sharing. These partnerships facilitate the development of novel therapies and improve existing treatment options. Licensing agreements and joint ventures also help companies expand their product pipelines and market reach. Such strategic alliances often lead to accelerated clinical trials and regulatory approvals, reducing time-to-market. Furthermore, collaborations with healthcare providers and patient advocacy groups enhance awareness and patient engagement, which can increase market penetration and adoption of new therapies, supporting overall market growth.
• Market Expansion in Emerging Regions: Growing healthcare infrastructure and increasing awareness in emerging markets such as Asia-Pacific and Latin America are opening new avenues for market expansion. These regions are witnessing rising healthcare expenditure and improved access to diagnostics and treatments. Local regulatory reforms and government initiatives aimed at rare diseases further facilitate market entry. As awareness and diagnosis rates improve, demand for effective therapies rises, attracting pharmaceutical investments. Market expansion in these regions not only increases sales volumes but also diversifies revenue streams, making the market more resilient and globally integrated.

The challenges facing this PNH and aHUS market include:

• High Treatment Costs: The therapies for PNH and aHUS, particularly complement inhibitors, are expensive, often costing hundreds of thousands of dollars annually. These high costs pose barriers to patient access, especially in low- and middle-income countries. Insurance coverage and reimbursement policies vary, impacting affordability and market penetration. The financial burden on healthcare systems can lead to restrictions on treatment availability, limiting market growth. Additionally, the high costs may deter pharmaceutical companies from investing in further R&D for these rare diseases, potentially slowing innovation and the development of more affordable options.
• Stringent Regulatory Hurdles: Despite supportive policies, the approval process for new therapies remains complex and lengthy. Regulatory agencies require extensive clinical data to demonstrate safety and efficacy, which can delay product launches. For rare diseases like PNH and aHUS, recruiting sufficient patient populations for trials is challenging, further complicating approval processes. Variability in regulatory requirements across regions can also hinder global market access. These hurdles increase development costs and timeframes, impacting profitability and slowing the introduction of innovative treatments, thereby restraining market growth.
• Limited Patient Population and Market Size: PNH and aHUS are rare disorders, resulting in a small patient pool. This limited market size can reduce the incentive for pharmaceutical companies to invest heavily in research and development, given the lower potential returns. Additionally, diagnosis rates are still improving, and many patients remain undiagnosed or misdiagnosed, further constraining market expansion. The small patient base also complicates clinical trial recruitment, delaying approval and commercialization. These factors collectively pose significant challenges to sustaining long-term growth and innovation within the market.

In summary, the PNH and aHUS market is driven by technological innovations, increasing diagnosis rates, supportive regulatory frameworks, strategic collaborations, and regional expansion. However, high treatment costs, regulatory complexities, and a limited patient population present notable challenges. These factors collectively shape the markets trajectory, requiring stakeholders to navigate carefully to maximize opportunities. While growth prospects remain promising, addressing these challenges is crucial for ensuring broader access to therapies and sustained market development. Overall, the markets evolution will depend on balancing innovation with affordability and regulatory efficiency.

List of PNH and aHUS Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies PNH and aHUS companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the PNH and aHUS companies profiled in this report include-

• Alexion Pharmaceuticals
• Apellis Pharmaceuticals
• Roche Holding AG
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Johnson & Johnson
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals

PNH and aHUS Market by Segment

The study includes a forecast for the global PNH and aHUS market by treatment type, diagnosis, end use, and region.

PNH and aHUS Market by Treatment Type [Value from 2019 to 2031]:

• Eculizumab
• Ravulizumab
• Others

PNH and aHUS Market by Diagnosis [Value from 2019 to 2031]:

• Flow Cytometry
• Genetic Testing
• Others

PNH and aHUS Market by End Use [Value from 2019 to 2031]:

• Hospitals
• Specialty Clinics
• Research Institutes
• Others

PNH and aHUS Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the PNH and aHUS Market

The PNH and aHUS market has experienced significant shifts driven by technological advancements, regulatory changes, and increasing awareness of these rare blood disorders. As research progresses, new therapies and diagnostic tools are emerging, impacting patient management and treatment options worldwide. Countries are adopting innovative approaches to improve outcomes, with a focus on personalized medicine and expanding access to care. The evolving landscape reflects a growing commitment to addressing unmet needs and enhancing the quality of life for affected individuals. These developments are particularly notable in major markets such as the United States, China, Germany, India, and Japan, each contributing uniquely to the global progress in PNH and aHUS management.

• United States: The US market has seen the approval of new complement inhibitors, expanding treatment options for PNH and aHUS. Increased investment in research and development, along with improved diagnostic techniques, has enhanced early detection and personalized therapy. Regulatory agencies are streamlining approval processes for innovative drugs, and patient advocacy groups are actively raising awareness. Telemedicine and digital health tools are also being integrated into patient care, improving access and monitoring.
• China: China is rapidly advancing in biotech research, with several local companies developing novel therapies for PNH and aHUS. Government initiatives support innovation and clinical trials, leading to faster drug approvals. The market is witnessing increased adoption of biosimilars and generic options, making treatments more affordable. Efforts are underway to improve diagnostic infrastructure and expand access to specialized care, especially in rural areas.
• Germany: Germany remains a leader in Europe for PNH and aHUS management, with a focus on integrating advanced diagnostics and personalized medicine. The country has seen the introduction of new therapeutic agents and improved treatment protocols. Strong healthcare infrastructure and research collaborations facilitate clinical trials and innovation. Patient-centered approaches and comprehensive care models are enhancing treatment outcomes.
• India: India is experiencing growth in the PNH and aHUS market, driven by rising awareness and improved healthcare infrastructure. Local pharmaceutical companies are developing cost-effective therapies and biosimilars to increase affordability. Government programs aim to strengthen diagnostic capabilities and expand access to specialized care. Increasing clinical research activity is contributing to a better understanding of disease patterns and treatment responses.
• Japan: Japan continues to innovate with the development of targeted therapies and advanced diagnostic tools for PNH and aHUS. The country emphasizes precision medicine and early diagnosis, supported by robust healthcare systems. Regulatory agencies are facilitating faster approval processes for new treatments. Ongoing research collaborations and clinical trials are further advancing the understanding and management of these rare disorders.

Features of the Global PNH and aHUS Market

• Market Size Estimates: PNH and aHUS market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: PNH and aHUS market size by treatment type, diagnosis, end use, and region in terms of value ($B).
• Regional Analysis: PNH and aHUS market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different treatment type, diagnosis, end use, and regions for the PNH and aHUS market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the PNH and aHUS market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the PNH and aHUS market by treatment type (eculizumab, ravulizumab, and others), diagnosis (flow cytometry, genetic testing, and others), end use (hospitals, specialty clinics, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global PNH and aHUS Market by Treatment Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Treatment Type
• 4.3 Eculizumab : Trends and Forecast (2019-2031)
• 4.4 Ravulizumab : Trends and Forecast (2019-2031)
• 4.5 Others : Trends and Forecast (2019-2031)

5. Global PNH and aHUS Market by Diagnosis

• 5.1 Overview
• 5.2 Attractiveness Analysis by Diagnosis
• 5.3 Flow Cytometry : Trends and Forecast (2019-2031)
• 5.4 Genetic Testing : Trends and Forecast (2019-2031)
• 5.5 Others : Trends and Forecast (2019-2031)

6. Global PNH and aHUS Market by End Use

• 6.1 Overview
• 6.2 Attractiveness Analysis by End Use
• 6.3 Hospitals : Trends and Forecast (2019-2031)
• 6.4 Specialty Clinics : Trends and Forecast (2019-2031)
• 6.5 Research Institutes : Trends and Forecast (2019-2031)
• 6.6 Others : Trends and Forecast (2019-2031)

7. Regional Analysis

• 7.1 Overview
• 7.2 Global PNH and aHUS Market by Region

8. North American PNH and aHUS Market

• 8.1 Overview
• 8.2 North American PNH and aHUS Market by Treatment Type
• 8.3 North American PNH and aHUS Market by End Use
• 8.4 The United States PNH and aHUS Market
• 8.5 Canadian PNH and aHUS Market
• 8.6 Mexican PNH and aHUS Market

9. European PNH and aHUS Market

• 9.1 Overview
• 9.2 European PNH and aHUS Market by Treatment Type
• 9.3 European PNH and aHUS Market by End Use
• 9.4 German PNH and aHUS Market
• 9.5 French PNH and aHUS Market
• 9.6 Italian PNH and aHUS Market
• 9.7 Spanish PNH and aHUS Market
• 9.8 The United Kingdom PNH and aHUS Market

10. APAC PNH and aHUS Market

• 10.1 Overview
• 10.2 APAC PNH and aHUS Market by Treatment Type
• 10.3 APAC PNH and aHUS Market by End Use
• 10.4 Chinese PNH and aHUS Market
• 10.5 Indian PNH and aHUS Market
• 10.6 Japanese PNH and aHUS Market
• 10.7 South Korean PNH and aHUS Market
• 10.8 Indonesian PNH and aHUS Market

11. ROW PNH and aHUS Market

• 11.1 Overview
• 11.2 ROW PNH and aHUS Market by Treatment Type
• 11.3 ROW PNH and aHUS Market by End Use
• 11.4 Middle Eastern PNH and aHUS Market
• 11.5 South American PNH and aHUS Market
• 11.6 African PNH and aHUS Market

12. Competitor Analysis

• 12.1 Product Portfolio Analysis
• 12.2 Operational Integration
• 12.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

• 13.1 Value Chain Analysis
• 13.2 Growth Opportunity Analysis
  • 13.2.1 Growth Opportunity by Treatment Type
  • 13.2.2 Growth Opportunity by Diagnosis
  • 13.2.3 Growth Opportunity by End Use
• 13.3 Emerging Trends in the Global PNH and aHUS Market
• 13.4 Strategic Analysis
  • 13.4.1 New Product Development
  • 13.4.2 Certification and Licensing
  • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

• 14.1 Competitive Analysis Overview
• 14.2 Alexion Pharmaceuticals
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.3 Apellis Pharmaceuticals
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.4 Roche Holding AG
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.5 Novartis AG
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.6 Pfizer Inc.
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.7 Sanofi S.A.
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.8 Johnson & Johnson
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.9 Amgen Inc.
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.10 Takeda Pharmaceutical Company Limited
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 14.11 Regeneron Pharmaceuticals
  • Company Overview
  • PNH and aHUS Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

15. Appendix

• 15.1 List of Figures
• 15.2 List of Tables
• 15.3 Research Methodology
• 15.4 Disclaimer
• 15.5 Copyright
• 15.6 Abbreviations and Technical Units
• 15.7 About Us
• 15.8 Contact Us